GMKBExpert Review of Cardiovascular Therapy – This article describes the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics, and effectiveness.
IGNITE Network analysis of challenges to implementing genomics in practice featured on GenomeWeb
GenomeWeb – Duke University led this effort to identify key challenges to and potential solutions for implementing genomics in practice based on information from IGNITE’s six member projects. (A free subscription is required to view this article.)
IGNITE Network highlighted at Precision Medicine World Conference 2017
BioQuick News – Duke University’s Dr. Geoffrey Ginsburg, co-chair and speaker at the 2017 Precision Medicine World Conference, presented the IGNITE Network’s achievements and aspirations to advance the implementation of genomics in practice.
Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network
BMC Medical Genomics – The objective of this study was to synthesize data on challenges identified by six diverse projects that are part of a National Human Genome Research Institute (NHGRI)-funded network focused on implementing genomics into practice and strategies to overcome these challenges.
Institutional profile: University of Florida Health Personalized Medicine Program
Pharmacogenomics – We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
Clinical Translational Science – One of the challenges hindering genomic implementation is the limited data on the outcomes and cost‐effectiveness of genotype‐guided drug therapy. The IGNITE network, consisting of institutions funded in the network and affiliate members, includes a number of institutions that have implemented pharmacogenetic testing to assist with prescribing decisions.
Cardiovascular Pharmacogenomics – Implications for Patients with Chronic Kidney Disease
Advances in Chronic Kidney Disease – Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease. Thus, patients with CKD often require treatment with cardiovascular drugs, such as antiplatelet, antihypertensive, anticoagulant, and lipid-lowering agents. There is significant inter-patient variability in response to cardiovascular therapies, which contributes to risk for treatment failure or adverse drug effects.
Race, Genomics and Chronic Disease: What Patients with African Ancestry Have to Say
Journal of Health Care for the Poor and Underserved – To translate genomic discoveries into practice, we gathered information about effects and challenges incorporating genetic risk in clinical care.
High-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine
Clinical and Translational Science – In this article, we review high‐throughput assays that have been developed to assess a variety of the functional impacts of the variants.
Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice
Value in Health – Implementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health